UIC
ABBV icon

Uniplan Investment Counsel’s AbbVie ABBV Stock Holding History

Uniplan Investment Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,800
Closed -$3.65M – 176
2026
Q1 		$3.65M Sell
16,800
-556
-3% -$123K 0.38% 71
2025
Q4 		$3.97M Buy
17,356
+486
+3% +$111K 0.4% 72
2025
Q3 		$3.91M Sell
16,870
-1,145
-6% -$233K 0.38% 68
2025
Q2 		$3.34M Sell
18,015
-10,080
-36% -$1.87M 0.34% 77
2025
Q1 		$5.89M Sell
28,095
-1,170
-4% -$227K 0.57% 48
2024
Q4 		$5.2M Sell
29,265
-21,174
-42% -$3.89M 0.48% 55
2024
Q3 		$9.96M Sell
50,439
-3,072
-6% -$573K 0.87% 30
2024
Q2 		$9.18M Sell
53,511
-954
-2% -$158K 0.83% 32
2024
Q1 		$9.92M Sell
54,465
-8,875
-14% -$1.53M 0.78% 34
2023
Q4 		$9.8M Sell
63,340
-4,462
-7% -$651K 0.73% 34
2023
Q3 		$9.13M Hold
67,802
– – 0.7% 41
2023
Q2 		$9.13M Sell
67,802
-1,551
-2% -$227K 0.66% 42
2023
Q1 		$11.1M Sell
69,353
-225
-0.3% -$34.4K 0.78% 35
2022
Q4 		$11.2M Buy
69,578
+5,699
+9% +$874K 0.8% 33
2022
Q3 		$8.57M Buy
63,879
+1,513
+2% +$217K 0.66% 39
2022
Q2 		$9.55M Buy
62,366
+4,807
+8% +$735K 0.67% 37
2022
Q1 		$9.33M Sell
57,559
-499
-0.9% -$72.5K 0.55% 41
2021
Q4 		$7.86M Sell
58,058
-2,498
-4% -$295K 0.44% 44
2021
Q3 		$6.53M Sell
60,556
-301
-0.5% -$34.4K 0.4% 50
2021
Q2 		$6.85M Sell
60,857
-4,076
-6% -$459K 0.4% 47
2021
Q1 		$7.03M Sell
64,933
-5,135
-7% -$549K 0.45% 47
2020
Q4 		$7.51M Sell
70,068
-8,942
-11% -$859K 0.51% 45
2020
Q3 		$6.92M Sell
79,010
-5,357
-6% -$504K 0.48% 46
2020
Q2 		$8.28M Sell
84,367
-11,271
-12% -$992K 0.58% 41
2020
Q1 		$7.29M Buy
95,638
+6,183
+7% +$527K 0.55% 43
2019
Q4 		$7.92M Sell
89,455
-5,991
-6% -$497K 0.47% 52
2019
Q3 		$7.23M Buy
+95,446
New +$6.54M 0.45% 50

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Uniplan Investment Counsel's ABBV Position: Q2 2026 in Review

Uniplan Investment Counsel sold out of AbbVie (ABBV) in Q2 2026, closing a stake of 16,800 shares — an estimated $3.65M sold.

Uniplan Investment Counsel first reported a position in ABBV in Q3 2019 and held it in 27 quarters. The position peaked at $11.2M in Q4 2022. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Uniplan Investment Counsel reported no remaining AbbVie position as of Q2 2026 after selling out during the quarter.
  • Uniplan Investment Counsel sold 16,800 AbbVie shares in Q2 2026, an estimated $3.65M.
  • Uniplan Investment Counsel first reported a position in AbbVie in Q3 2019 and held it in 27 quarters.
  • Uniplan Investment Counsel's AbbVie position peaked at $11.2M in Q4 2022.
  • 4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.